bioRxiv · 10.64898/2026.11.12.765851
SLC25A39 loss disrupts mitochondrial redox homeostasis and exposes therapeutic vulnerabilities in glioblastoma
Abstract
Glioblastoma is an incurable brain tumour characterised by extensive hypoxia and phenotypic plasticity, both of which drive therapy resistance. Mitochondrial glutathione, dependent on the inner membrane carrier SLC25A39, is central to buffering the oxidative stress that hypoxia generates; its regulation and significance in glioblastoma are nonetheless unknown. We find that SLC25A39 expression is hypoxia-inducible and HIF-dependent, enriched in hypoxic tumour niches and heterogeneously expressed within and between tumours. Its loss depletes mitochondrial glutathione, causing oxidative damage to nucleic acids and lipids, mitochondrial hyperfusion, impaired respiration and a compensatory shift towards glycolysis, glutamine catabolism and serine synthesis. SLC25A39-deficient cells grow poorly, yet resist temozolomide while becoming markedly sensitive to navitoclax, an inhibitor of Bcl-2 and Bcl-xL, which increases cell killing when combined with radiation and temozolomide. In this work, we identify SLC25A39 as a metabolic vulnerability and candidate stratification marker in glioblastoma.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Eales, K. L., Lyu, Y., Feng, Y., Rajgopal, I., Chowdhury, S. R., Marzullo, B., Palmer-Coulson, H., Nixon, C., Roberts, J., Wykes, V., Prudent, J., Hua, W., Tennant, D. A.. 2026-11-16. SLC25A39 loss disrupts mitochondrial redox homeostasis and exposes therapeutic vulnerabilities in glioblastoma. https://doi.org/10.64898/2026.11.12.765851
Cite the original work for its findings. Save a collection to share your selection of sources.